Skip to main content

Site notifications

Clopidogrel Tablets, USP 75mg (Novadoz, USA)

Section 19A approved medicine
Clopidogrel Tablets, USP 75mg (Novadoz, USA)
Section 19A approval holder
Phero Pharma Pty Ltd ABN 96 673 730 231
Phone
02 9420 9199
Approved until
Status
Current
Medicines in short supply/unavailable
PLIDOGREL clopidogrel (as besilate) 75 mg tablet blister pack - ARTG 218326
CLOPIDOGREL SANDOZ PHARMA clopidogrel (as hydrogen sulfate) 75 mg, film coated tablets, blister pack - ARTG 187042
Indication(s)

Prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease.

Clopidogrel is indicated in combination with aspirin for patients with:

  • Unstable angina or non-ST-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). Clopidogrel is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or PCI, with or without stent).
  • ST-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. In this population, clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.
Images
Picture of Clopidogrel tablets USP 75mg - bottle label
Picture of Clopidogrel tablets USP 75mg - bottle